This Author published in this journals
All Journal Narra J
Reviany V. Nidom
Professor Nidom Foundation, Surabaya, Indonesia; Global Biosains Teknologi, Malang, Indonesia; Riset AIRC Indonesia, Surabaya, Indonesia

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

Enhancing immunogenicity: Evaluating the polio antigen immune response in hexavalent vaccine formulations Tiza Wuri Mawaddah; Elisa D. Pratiwi; Arif Rahman Sadjuri; Dimas Tri Nugroho; Arip Hidayat; Acep R. Wijayadikusumah; Astria N. Nidom; Zakiyyan I. Ayyuba; Kadek Rachmawati; Suwarno Suwarno; Jola Rahmahani; Setyarina Indrasari; Reviany V. Nidom; Chairul A. Nidom
Narra J Vol. 6 No. 3 (2026): December 2026 (In Press)
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v6i3.3140

Abstract

Hexavalent vaccines simplify childhood immunization by combining antigens against six diseases in a single formulation; however, the immunogenicity of each component must be evaluated. This study assessed poliovirus-specific immunoglobulin G (IgG) responses elicited by candidate hexavalent vaccines containing different doses of Sabin strain-derived inactivated poliovirus vaccine (sIPV). A preclinical study was conducted using 40 Wistar rats allocated to five groups: hexavalent vaccine containing low-, medium-, or high-dose sIPV; pentavalent vaccine combined with sIPV; or adjuvant control. Each group comprised four male and four female rats. The animals received primary immunization at week 0 and booster doses at weeks 4 and 8. Serotype-specific IgG titers were measured at weeks 0, 4, 8, and 12 using indirect enzyme-linked immunosorbent assay. Antibody responses were analyzed using repeated-measures analysis of variance. Titers against poliovirus serotypes 1, 2, and 3 were negligible at baseline and remained low at week 4. Marked responses were observed in all vaccinated groups at week 8, followed by lower titers at week 12. Significant between-group differences were detected at weeks 8 and 12 for serotype 1 (p<0.001 and p=0.010), serotype 2 (both p<0.001), and serotype 3 (both p=0.010). However, no consistent dose–response pattern was observed across serotypes, time points, or sexes. All animals survived and gained body weight during follow-up. The candidate hexavalent formulations elicited marked poliovirus-specific binding-IgG responses, supporting further preclinical evaluation using validated serological and serotype-specific neutralization assays.